Form 4: Corbus CMO Sells Shares for Tax Obligations

Corbus Pharmaceuticals' Chief Medical Officer, Dominic Smethurst, sold 3,285 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Dominic Smethurst, Chief Medical Officer of Corbus Pharmaceuticals Holdings, Inc., sold 3,285 shares of common stock.
• The transaction occurred on February 3, 2026, at a weighted average price of $8.0898 per share, with prices ranging from $8.01 to $8.15.
• The sale was a 'sell to cover' transaction, mandated by the Issuer, to satisfy tax withholding obligations arising from the vesting and settlement of Restricted Stock Units (RSUs).
• This was not a discretionary transaction by Mr. Smethurst.
• Following the transaction, Mr. Smethurst beneficially owns 95,887 shares of common stock, which includes 86,265 unvested RSUs.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine, non-discretionary transaction for tax purposes related to equity compensation, which is a common occurrence for executives and does not signal a change in company fundamentals or management's outlook.

Positives

• The sale was non-discretionary, solely to cover tax obligations from RSU vesting, indicating a pre-planned event rather than a voluntary divestment.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, demonstrating pre-planning and compliance with insider trading regulations.

Negatives

• A reduction in direct share ownership by a key executive, even if for tax purposes, could be perceived negatively by some investors who prefer to see executives increasing their stake.

Future Outlook

NA

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ('RSUs').
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common and standard practice for executives to manage tax liabilities arising from equity compensation vesting, particularly with Restricted Stock Units. This type of transaction is generally not indicative of a change in management's confidence in the company's future, unlike discretionary sales.

Comparison to Industry Standards

• This 'sell to cover' transaction aligns with common industry practices for managing tax obligations related to equity compensation, similar to how executives at biotech peers like Moderna or Pfizer handle RSU vesting.
• The use of a Rule 10b5-1(c) plan for such transactions is a standard corporate governance measure to demonstrate pre-planning and avoid accusations of insider trading, a practice widely adopted across S&P 500 companies.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in direct insider ownership, but its non-discretionary nature mitigates concerns typically associated with insider selling.
• Employees: Reflects standard equity compensation practices for executives, indicating the vesting of previously granted Restricted Stock Units.

Key Dates

Recommendation

The transaction is a routine 'sell to cover' for tax obligations related to RSU vesting, not a discretionary sale indicating a change in management's outlook. As such, it does not provide new information that would alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Corbus Pharmaceuticals, CRBP, Form 4, Insider Transaction, Dominic Smethurst, Chief Medical Officer, RSU vesting, Sell to Cover, Equity Compensation